KVUEQueued from the May 25, 2026 S&P 500 market-cap snapshot ranks 251-275; rankApprox is set to the cohort midpoint because no more granular rank was provided in the intake.

Kenvue

Kenvue sells consumer health products across self-care, skin health and beauty, and essential health brands.

CompaniesMarketCap Product analyses

Metadata

Where this company sits

Ticker: KVUE
Rank snapshot: ≈ 263
Sector: Consumer Staples
Industry: Household Products
Region: United States
Index: S&P 500 · Top 275 by market cap

Metrics

Scoring view

Every metric is paired with a short rationale. The numbers are deliberate, not divine.

Moat

8.0/10

Kenvue owns many high-recognition consumer health brands, serves a large global user base, operates in trust-sensitive categories, and benefits from retail distribution, professional recommendation, and compliance scale.

Decentralizability

4.0/10

Physical health and beauty products face formulation, safety, labeling, manufacturing, and liability barriers, but generics, transparent ingredient data, cooperative procurement, refill systems, and local packaging loops create partial decentralization paths.

Profitability

6.0/10

CompaniesMarketCap reported 2026 trailing revenue of about $15.29 billion and 2026 trailing EBIT of about $2.21 billion, indicating a profitable but not unusually high-margin consumer staples business.

Price / Earnings

21.3x

CompaniesMarketCap reported Kenvue's trailing P/E ratio at about 21.3 as of June 2026; this is a point-in-time market metric and can move daily.

Market cap

$36.7B

CompaniesMarketCap reported Kenvue's market capitalization at about $36.72 billion as of June 2026, with an end-of-day June 26, 2026 figure of about $36.72 billion.

Freed-up capital potential

$4.2B

Derived from market cap, moat resistance, decentralizability, and profitability. It is a directional estimate of value capture that could come under pressure if open alternatives compound.

IPO market cap

$41.0B

Kenvue's IPO was priced at $22 per share and reported as valuing the company at about $41 billion on its first trading day; this is treated as the IPO-era equity valuation.

IPO return multiplier

0.9x

Current market cap divided by the IPO market cap implied on 2023-05-04.

Yearly market cap growth since IPO

-3.4%

Compound annual market cap growth from the IPO date 2023-05-04 through the snapshot date 2026-06-27.

Narrative

Why the company matters

A short editorial overview plus the current thesis on moat strength and decentralization pressure.

Consumer health portfolio

Kenvue is a large pure-play consumer health company with 2025 net sales of about $15.1 billion across self care, skin health and beauty, and essential health brands.

Its portfolio includes Tylenol, Neutrogena, Aveeno, Band-Aid, Listerine, Nicorette, Johnson's, and Zyrtec, with products reaching consumers through pharmacies, mass retail, grocery, e-commerce, and professional recommendation channels.

Pending transaction context

Kimberly-Clark and Kenvue describe their proposed cash-and-stock transaction as valuing Kenvue at about $48.7 billion of enterprise value, with closing expected in the second half of 2026 subject to regulatory approvals and customary conditions.

Until that transaction closes, Kenvue remains a public consumer health company in the registry, but the proposed combination reinforces that the business is strategically valued for scale, global brands, retail access, manufacturing capacity, and consumer trust.

Registry relevance

Kenvue is relevant to the registry because its products sit at the edge of brand trust, regulated consumer health, commodity chemistry, retail distribution, and repeat household purchasing.

The strongest decentralization pressure is not a direct open-source clone of Kenvue's full portfolio. It is pressure from generics, transparent labels, independent batch verification, cooperative procurement, refill infrastructure, reusable packaging, and local production for simpler non-drug personal care categories.

Moat reading

Kenvue's moat comes from trusted brands, healthcare-professional credibility, retail shelf access, formulation know-how, regulatory compliance systems, and the difficulty of earning consumer trust in pain relief, skincare, baby care, wound care, and oral care.

The moat is strongest where safety and credibility matter, such as Tylenol's acetaminophen franchise and Neutrogena's dermatologist-developed skincare positioning. It is weaker where the underlying chemistry is generic or where consumer behavior can shift toward refill, transparency, or lower-cost private-label alternatives.

Decentralization reading

Kenvue is a low-to-moderate decentralization target because most products are physical consumables with safety, quality, labeling, manufacturing, and distribution constraints. OTC drugs and sunscreen-adjacent products are especially hard to decentralize honestly because incorrect dosing, contamination, or false claims can create real harm.

Credible openings still exist. Generic acetaminophen already weakens brand exclusivity, while open regulatory data, DailyMed labeling, FDA safety materials, cosmetics product-listing requirements, open biomaterials databases, and local recycling projects can support more transparent procurement, refill, reuse, and batch-verification networks.

Products

Where the moat actually touches users

These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 2 structured disruption concepts across the current product set.

2 disruption concepts tracked0 documented exceptions

Tylenol

OTC pain relief and fever reduction

1 concept

Tylenol is Kenvue's acetaminophen-based over-the-counter pain relief and fever reduction brand, spanning adult, children, infant, cold, flu, sleep, and topical pain formats.

Open analysis

Neutrogena

Skin health and beauty

1 concept

Neutrogena is Kenvue's dermatologist-developed skincare and beauty brand, spanning cleansers, moisturizers, acne care, sunscreens, makeup, body care, hair care, and skin analysis tools.

Open analysis

Technology waves

Strategic lenses

These are the repo's explicit bias terms: the technologies expected to keep making incumbents less inevitable over time.

Microfactories and automated mini-home production

Small, software-defined manufacturing cells could make localized production less eccentric and more default.

• Products with heavy branding but generic bill-of-materials profiles look increasingly vulnerable.
• Logistics moats still matter, but their margin for arrogance should narrow.
• Open-source production recipes can pressure both price and product differentiation.

Paper trail

Visible evidence trail

These sources shaped the scoring and writing. The site is opinionated, but it should not behave like it is improvising facts in a dark room.

Open source on GitHub

Kenvue Inc. - Investor Relations

Kenvue · investor relations

Company overview source for Kenvue's 2025 net sales, segment framing, global reach, people served, and core brand portfolio.

Reviewed 2026-06-27

Our brands

Kenvue · product page

Primary portfolio source for Kenvue's self care, skin health and beauty, and essential health categories, including Tylenol and Neutrogena.

Reviewed 2026-06-27

Kimberly-Clark + Kenvue: Creating a Global Health and Wellness Leader

Kimberly-Clark and Kenvue · investor relations

Official transaction-information site documenting the proposed Kimberly-Clark and Kenvue combination, enterprise value, consideration, expected timing, and closing conditions.

Reviewed 2026-06-27

Kenvue (KVUE) - Market capitalization

CompaniesMarketCap · market data

Point-in-time market capitalization source for Kenvue, including the June 2026 market-cap figure.

Reviewed 2026-06-27

Kenvue (KVUE) - P/E ratio

CompaniesMarketCap · market data

Point-in-time trailing P/E ratio source for Kenvue.

Reviewed 2026-06-27

Kenvue (KVUE) - Revenue

CompaniesMarketCap · market data

Revenue-history source used to benchmark Kenvue's scale and profitability context.